Comments
Natco Pharma has received final approval from the US Food and Drug administration (USFDA) for its Abbreviated New Drug Application for the generic version of Vidaza (Azacitidine for Injection). The Hyderabad-based Natco and its marketing partner Breckenridge Pharmaceutical, Inc. were planning to launch the product in the US market, the company said in a release. Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome. Vidaza generated total combined sales of $188 million for the 12 months ended April 2017, based on the industry sales data. Our Bureau
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.